An interventional study of High-definition transcranial direct current stimulation and Cognitive remediation therapy in Schizophrenia / Schizoaffective Disorder, sponsored by Beth Israel Deaconess Medical Center. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Beth Israel Deaconess Medical Center · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Schizophrenia by Beth Israel Deaconess Medical Center — 3 open to participants now, 4 under way, 1 of them phase 3. Schizophrenia · Beth Israel Deaconess Medical Center.
Among the 16 studies in Schizophrenia by Beth Israel Deaconess Medical Center, this one is the 12th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2026, is one of 10 with no phase, and was the 16th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →3 of the 16 studies in Schizophrenia by Beth Israel Deaconess Medical Center are open now, in 1 country. Recruiting first, the newest first:
Beth Israel Deaconess Medical Center · Sites in United States
Ages 18–40
Beth Israel Deaconess Medical Center · Sites in United States
Ages 18–65
By country, each count listing its studies:
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 40 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 2
First in 2001; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10 is below the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 20 across the 15 interventional studies, 320 across the 1 observational. Of the 11 that completed or were terminated, 7 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
Beth Israel Deaconess Medical Center is the lead sponsor of 570 studies on the registry; 81 are open to participants now.
Of its 76 completed or terminated interventional studies of FDA-regulated products, 62 (82%) have results posted.
2 of the studies in Schizophrenia by Beth Israel Deaconess Medical Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06740383Beth Israel Deaconess Medical CenterBiomarkers/Biotypes, Course of Early Psychosis and Specialty Services | 2027-06-30 |
| NCT07940712Beth Israel Deaconess Medical CenterCognitive Augmentation, Remediation, and TDCS for Schizophrenia | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies in Schizophrenia by Beth Israel Deaconess Medical Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Schizophrenia-spectrum disorders (SSDs; schizophrenia, schizoaffective disorder, etc.) are among the most disabling and costly conditions globally. Most SSD medications treat symptoms like hallucinations and delusions, but cognitive symptoms, or problems with thinking, memory, and problem solving, remain untreated by medication. Other developing treatments for these symptoms include noninvasive stimulation of cognitive brain regions and behavioral therapies involving mental skill-building activities. While both of these treatments appear to improve cognitive symptoms, effects are inconsistent depending on specific details of the trial. Growing evidence suggests that using these therapies together could lead to larger, clinically meaningful effects. Still, prior combined therapy trials use simplified versions of the behavioral therapy, omitting the guidance of a therapist to engage and challenge the participant. These previous trials show some evidence for beneficial effects, particularly in working memory, but the omission of a therapist could limit effects. This study will be the first to test if using a comprehensive, therapist-guided behavioral therapy can amplify the effects of noninvasive brain stimulation (NIBS) to reduce cognitive symptoms and change brain activity in SSDs. We will conduct a small pilot study to gather preliminary evidence for this combined therapy using 10 participants split into 2 groups. One group will receive NIBS and comprehensive cognitive therapy (NIBS+) while the other receives NIBS and performs quizzes without the guidance of a therapist (NIBS-). Participants will receive therapies for 10 days over 2 weeks with 2 hours of therapy per day. We will compare interventions through the following aims. Aim 1 will examine changes in brain connections after NIBS+ and NIBS-. We will collect data from electrical brain recordings (electroencephalography/EEG) before and after interventions. We expect that connections between cognitive brain regions will be most strengthened by NIBS+ compared to NIBS-. Aim 2 will investigate what kind of cognitive symptoms are affected by NIBS+ and NIBS-. We will perform cognitive tests before and after the interventions. We expect that all cognitive symptoms (memory, motor speed, language skills, attention, processing speed, and planning abilities) will be most improved by NIBS+ compared to NIBS-, but that the largest improvements will be in short-term, active memory skills ("working memory"). We will also investigate if there is a relationship between the changes in brain connections and cognitive improvements.
This preliminary study will provide early evidence that the effects of noninvasive brain stimulation can be strengthened by a structured, therapist-guided behavioral therapy for cognitive symptoms. This will support the development of a new, combined therapy for untreated cognitive symptoms in schizophrenia-spectrum disorders. We will use findings of this study to support a trial proposal to the National Institute of Mental Health to test this therapy in a larger group of individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Combined transcranial direct current stimulation and cognitive remediation therapy (both active)
Device: High-definition transcranial direct current stimulation · Behavioral: Cognitive remediation therapy
Transcranial direct current stimulation and sham cognitive remediation therapy (active tDCS and sham CRT)
Device: High-definition transcranial direct current stimulation · Behavioral: Sham cognitive remediation therapy
Active HD-tDCS delivered to the left dorsolateral prefrontal cortex
Also known as: HD-tDCS
Active cognitive remediation therapy. Cognitive exercises are delivered with NeuropsychOnline and administered by a trained coach.
Also known as: CRT
An active comparator for cognitive remediation therapy, delivered with quizzes collected from Sporcle.com.
Also known as: sham CRT
Functional connectivity with the prefrontal cortex
Participants will be directed to keep their eyes open and loosely fixed on a plus sign on the screen in front of them for 5 minutes while EEG is recorded. Resting data will be cleaned, processed, and transformed to 4 frequency band values: delta/theta, alpha, beta, and gamma. Frequency data will be converted to connectivity values using weighted phase lag index (wPLI). Average connectivity of all sensors with the prefrontal sensor F3 will be calculated and compared between timepoints.
Time frame: Pre-intervention to post-intervention at 2-weeks
Brief Assessment of Cognition Digit Sequencing (Working Memory)
Participants will arrange random number strings in ascending order during the Brief Assessment of Cognition. This score, which indexes working memory is called Digit Sequencing and will be z-scored according to published norms and compared between timepoints.
Time frame: Pre-intervention to post-intervention at 2-weeks
Brief Assessment of Cognition subdomains
Participants will complete the Brief Assessment of Cognition, which includes tasks indexing psychomotor and visual processing speed, lexical access, attention and processing speed, and executive functioning, called Token Motor, Verbal Fluency, Symbol Coding, and Tower of London, respectively. These subdomain scores will be normed and compared between timepoints.
Time frame: Pre-intervention to post-intervention at 2-weeks
Plan to share: Yes — Only IPD used in the results publication will be shared.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Nov 2027, 11 months later.
Of 760 non-industry interventional studies with no phase under Schizophrenia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's planned 11 months is below that.
Counting every sponsor, half of 773 studies reached it within 32 months; a quarter within 16 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Beth Israel Deaconess Medical Center →